InvestorsHub Logo
Followers 52
Posts 9070
Boards Moderated 1
Alias Born 10/25/2007

Re: DewDiligence post# 13238

Tuesday, 02/27/2024 9:15:34 AM

Tuesday, February 27, 2024 9:15:34 AM

Post# of 13431
Seems to have all it takes......The trial met both its primary efficacy endpoints, with a vaccine efficacy (VE) of 83.7% (95.88% CI: 66.1%, 92.2%; p<0.0001) against RSV-LRTD as defined by two or more symptoms, and a VE of 82.4% (96.36% CI: 34.8%, 95.3%; p=0.0078) against RSV-LRTD defined by three or more symptoms.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News